West Pharmaceutical stock gets higher 2026 outlook after Q3 growth

Published on 11/08/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock gets a higher full-year outlook after a strong third quarter. Management also lowered its capital-spending forecast.

Quarterly growth lifts annual outlook

West reported stronger third-quarter sales and earnings, led by demand for high-value product components.
Management raised its full-year sales and adjusted earnings outlook after the September quarter.
Lower planned capital spending adds another change to the companys full-year targets.

West Pharmaceutical, US9553061055, Illustration mit AI erstellt.

West Pharmaceutical Services raised its full-year 2026 sales and adjusted earnings outlook after reporting stronger third-quarter results on October 29. The company said in its third-quarter results release that demand for High-Value Product Components led the performance.

Growth led by high-value components

Third-quarter net sales reached USD 874.5 million, up 8.7 percent from the prior-year period. Organic sales growth was 11.9 percent. Reported diluted earnings per share rose 57.3 percent to USD 3.02, while adjusted diluted earnings per share increased 35.7 percent to USD 2.66.

The Proprietary Products segment generated USD 728.8 million in sales, an increase of 12.6 percent. High-Value Product Components sales climbed 19.7 percent to USD 466.7 million and represented 53 percent of total quarterly sales. West Vantage sales declined 7.3 percent to USD 145.7 million.

Higher targets for the full year

West lifted its 2026 net sales guidance to USD 3.41 billion to USD 3.42 billion from USD 3.345 billion to USD 3.380 billion. The organic growth outlook increased to 11.3 percent to 11.6 percent from 10 percent to 11 percent.

Adjusted diluted EPS is now expected at USD 9.38 to USD 9.48, compared with the previous range of USD 8.85 to USD 9.05. The company also reduced its capital spending forecast to USD 215 million to USD 220 million from USD 250 million to USD 275 million.

West Pharmaceutical stock traded at 358.80 euros on Lang & Schwarz at 13:02 CET on Saturday, November 7, 2026. Investors will focus next on whether demand in high-value components can sustain the raised outlook and offset weaker West Vantage sales.

For investors tracking the real-time quote of West Pharmaceutical stock, the company trades on the New York Stock Exchange under ticker WST and is included in the S&P 500.